mitoxantrone has been researched along with Hematologic Diseases in 38 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Hematologic Diseases: Disorders of the blood and blood forming tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a previous dose-finding trial, in previously treated patients with metastatic breast cancer (MBC), we showed that the combination of Mitoxantrone (M) and Paclitaxel (P) may be an interesting (response rate: 69%) and well-tolerated regimen." | 9.11 | Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research. ( Acito, L; Angiona, S; Bilancia, D; Di Costanzo, F; Gasperoni, S; Giustini, L; Manzione, L; Mazzoni, F, 2004) |
| "The combination of paclitaxel and mitoxantrone is active, easily administered, and well tolerated in the treatment of metastatic breast cancer." | 9.10 | Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: a phase II trial of the Minnie Pearl Cancer Research Network. ( Calvert, S; Greco, FA; Hainsworth, JD, 2002) |
| "54 patients with advanced breast cancer were randomised into a prospective, non-blinded, controlled trial to receive: mitoxantrone 28 mg/m2 intravenous day 1 and granulocyte-colony stimulating factor (G-CSF) 5 micrograms/kg/day subcutaneously days 2 to 16 (n = 27) or the same regimen plus thymostimulin (TS) 50 mg/day intramuscular at days 2 to 16 (n = 27)." | 9.08 | A randomised study comparing granulocyte-colony stimulating factor (G-CSF) with G-CSF plus thymostimulin in the treatment of haematological toxicity in patients with advanced breast cancer after high dose mitoxantrone therapy. ( Milla, A; Sanchiz, F, 1996) |
| "The maximum tolerated dose for a combination chemotherapy regimen of Thiotepa, Mitoxantrone and Methotrexate (TMM) administered intravenously every three weeks to twelve patients with metastatic breast cancer was: Thiotepa: 15mg/m2, Mitoxantrone: 10mg/m2 and Methotrexate: 30mg/m2." | 9.06 | A pilot trial of TMM (thiotepa, mitoxantrone and methotrexate) chemotherapy for metastatic breast cancer. ( Bhardwaj, S; Holland, JF, 1990) |
| "Three hundred twenty-five women with metastatic adenocarcinoma of the breast who had failed one prior chemotherapeutic regimen for advanced disease were randomized to receive 14 mg/m2 of mitoxantrone or 75 mg/m2 of doxorubicin intravenously (IV) every 3 weeks." | 9.06 | Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. ( Allegra, JC; Bryan, S; Cartwright, K; Dukart, G; Henderson, IC; Henry, D; Wolff, S; Woodcock, T, 1989) |
| "To exploit possible different non-cross-resistant mechanisms of cytotoxicity, 25 patients with advanced breast cancer were given combination chemotherapy consisting of iv mitoxantrone (7 mg/m2) and doxorubicin (30 mg/m2) every 3-4 weeks." | 9.06 | Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer. ( Ford, JM; Leclerc, Y; Margolese, R; Panasci, L, 1987) |
| "A total of 56 heavily pretreated patients with advanced breast cancer were treated with the combination mitomycin and mitoxantrone." | 7.67 | Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer. ( Bishop, JF; Burns, I; Coates, A; Hillcoat, BL; Jeal, PN; Raghavan, D; Tattersall, MN; Woods, R, 1987) |
| "Seventy-five patients with stage 4 breast cancer were treated with a first-line chemotherapy regimen consisting of cyclophosphamide 600 mg/m2, mitoxantrone 12 mg/m2, and vincristine 1." | 7.67 | First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine. ( Bezwoda, WR; Dansey, R; Seymour, L, 1989) |
| "Seventeen patients with relapsed or refractory acute nonlymphocytic leukemia were treated with 14 mg/m2 of mitoxantrone given in a 30-minute infusion daily for three days." | 7.67 | Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. ( Ball, ED; Cornell, CJ; Cornwell, GG; McIntyre, OR; Mills, LE; O'Donnell, JF; Vredenburgh, JJ, 1988) |
| "Eighteen women with metastatic breast cancer entered a phase I-II study of high-dose mitoxantrone (MXT)." | 7.67 | High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial. ( Leiby, JM; Neidhart, JA; Unverfurth, DV, 1986) |
| "To explore the therapeutic effect of homoharringtonine (HHT) combined with cytarabine (HA regimen) on CML-MBC and its influence on bone marrow CD34+CD7+ cells." | 6.79 | Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells. ( Deng, Z; Ding, B; Li, Y; Shi, Y; Zho, J, 2014) |
| "Mitoxantrone was administered intravenously at an initial dose of 12 mg/m2 and repeated every 3 weeks, with dose escalation to a maximum of 14 mg/m2." | 6.67 | Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanian Clinical Oncology Association Group study. ( Choi, P; Choy, D; Dugan, M; Lee, S; Leung, T; Ngai, A; Prasad, U; Sham, J; Shiu, W; Teo, P, 1993) |
| "In a previous dose-finding trial, in previously treated patients with metastatic breast cancer (MBC), we showed that the combination of Mitoxantrone (M) and Paclitaxel (P) may be an interesting (response rate: 69%) and well-tolerated regimen." | 5.11 | Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research. ( Acito, L; Angiona, S; Bilancia, D; Di Costanzo, F; Gasperoni, S; Giustini, L; Manzione, L; Mazzoni, F, 2004) |
| "The combination of paclitaxel and mitoxantrone is active, easily administered, and well tolerated in the treatment of metastatic breast cancer." | 5.10 | Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: a phase II trial of the Minnie Pearl Cancer Research Network. ( Calvert, S; Greco, FA; Hainsworth, JD, 2002) |
| "54 patients with advanced breast cancer were randomised into a prospective, non-blinded, controlled trial to receive: mitoxantrone 28 mg/m2 intravenous day 1 and granulocyte-colony stimulating factor (G-CSF) 5 micrograms/kg/day subcutaneously days 2 to 16 (n = 27) or the same regimen plus thymostimulin (TS) 50 mg/day intramuscular at days 2 to 16 (n = 27)." | 5.08 | A randomised study comparing granulocyte-colony stimulating factor (G-CSF) with G-CSF plus thymostimulin in the treatment of haematological toxicity in patients with advanced breast cancer after high dose mitoxantrone therapy. ( Milla, A; Sanchiz, F, 1996) |
| "The maximum tolerated dose for a combination chemotherapy regimen of Thiotepa, Mitoxantrone and Methotrexate (TMM) administered intravenously every three weeks to twelve patients with metastatic breast cancer was: Thiotepa: 15mg/m2, Mitoxantrone: 10mg/m2 and Methotrexate: 30mg/m2." | 5.06 | A pilot trial of TMM (thiotepa, mitoxantrone and methotrexate) chemotherapy for metastatic breast cancer. ( Bhardwaj, S; Holland, JF, 1990) |
| "Three hundred twenty-five women with metastatic adenocarcinoma of the breast who had failed one prior chemotherapeutic regimen for advanced disease were randomized to receive 14 mg/m2 of mitoxantrone or 75 mg/m2 of doxorubicin intravenously (IV) every 3 weeks." | 5.06 | Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. ( Allegra, JC; Bryan, S; Cartwright, K; Dukart, G; Henderson, IC; Henry, D; Wolff, S; Woodcock, T, 1989) |
| "To exploit possible different non-cross-resistant mechanisms of cytotoxicity, 25 patients with advanced breast cancer were given combination chemotherapy consisting of iv mitoxantrone (7 mg/m2) and doxorubicin (30 mg/m2) every 3-4 weeks." | 5.06 | Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer. ( Ford, JM; Leclerc, Y; Margolese, R; Panasci, L, 1987) |
| "A total of 56 heavily pretreated patients with advanced breast cancer were treated with the combination mitomycin and mitoxantrone." | 3.67 | Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer. ( Bishop, JF; Burns, I; Coates, A; Hillcoat, BL; Jeal, PN; Raghavan, D; Tattersall, MN; Woods, R, 1987) |
| "Seventy-five patients with stage 4 breast cancer were treated with a first-line chemotherapy regimen consisting of cyclophosphamide 600 mg/m2, mitoxantrone 12 mg/m2, and vincristine 1." | 3.67 | First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine. ( Bezwoda, WR; Dansey, R; Seymour, L, 1989) |
| "Seventeen patients with relapsed or refractory acute nonlymphocytic leukemia were treated with 14 mg/m2 of mitoxantrone given in a 30-minute infusion daily for three days." | 3.67 | Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. ( Ball, ED; Cornell, CJ; Cornwell, GG; McIntyre, OR; Mills, LE; O'Donnell, JF; Vredenburgh, JJ, 1988) |
| "Eighteen women with metastatic breast cancer entered a phase I-II study of high-dose mitoxantrone (MXT)." | 3.67 | High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial. ( Leiby, JM; Neidhart, JA; Unverfurth, DV, 1986) |
| "To explore the therapeutic effect of homoharringtonine (HHT) combined with cytarabine (HA regimen) on CML-MBC and its influence on bone marrow CD34+CD7+ cells." | 2.79 | Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells. ( Deng, Z; Ding, B; Li, Y; Shi, Y; Zho, J, 2014) |
| "The most effective regimen for relapsed acute myeloid leukemia (AML) patients who do not achieve complete remission (CR) after a course of salvage therapy has not been established." | 2.77 | Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy. ( Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C, 2012) |
| "Mitoxantrone has demonstrable clinical activity when administered intravenously in a wide range of malignancies." | 2.67 | Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. ( Aartsen, E; Dubbelman, R; Mandjes, I; McVie, JG; Oza, AM; Soepenberg, O; ten Bokkel Huinink, W, 1994) |
| "Mitoxantrone was administered intravenously at an initial dose of 12 mg/m2 and repeated every 3 weeks, with dose escalation to a maximum of 14 mg/m2." | 2.67 | Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanian Clinical Oncology Association Group study. ( Choi, P; Choy, D; Dugan, M; Lee, S; Leung, T; Ngai, A; Prasad, U; Sham, J; Shiu, W; Teo, P, 1993) |
| "Mitoxantrone (MTX) is an antineoplastic agent that can induce hepato- and haematotoxicity." | 1.40 | Cumulative mitoxantrone-induced haematological and hepatic adverse effects in a subchronic in vivo study. ( Arbo, M; Costa, VM; Dallegrave, E; de Lourdes Bastos, M; Dinis-Oliveira, RJ; Duarte, JA; Palmeira, C; Remião, F; Rossato, LG; Santos-Silva, A, 2014) |
| "Echocardiographic reports on 144 adults receiving anthracycline therapy and 18 controls were reviewed for the possible relationship between dosage and ejection fractions." | 1.30 | [Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy]. ( Horikawa, K; Okada, Y; Sano, M, 1997) |
| "Phase I and pharmacokinetic studies were performed in order to evaluate the maximum tolerated dose and the efficiency of 120 h continuous venous infusion (CVI) of mitoxantrone." | 1.28 | Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases. ( Bugat, R; Canal, P; Chevreau, C; de Forni, M; Huguet, F; Lachau, S; Laurent, G; Roche, H, 1991) |
| " From June 1988 to December 1989, 27 previously untreated patients with early-staged Hodgkin's disease with adverse features for disease-free survival received combined-modality therapy." | 1.28 | NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. ( Cabanillas, F; Hagemeister, FB; Liang, JC; McLaughlin, P; Meistrich, ML; Redman, JR; Rodríguez, MA; Romaguera, JE; Swan, F; Velásquez, WS, 1990) |
| " A dosage of 18 mg/m2 was administered as a short intravenous infusion every 3 weeks." | 1.27 | Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study. ( Etcubanas, E; Krance, RA; Mahoney, DH; Patterson, RB; Pratt, CB; Sexauer, C; Vietti, TJ, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (28.95) | 18.7374 |
| 1990's | 12 (31.58) | 18.2507 |
| 2000's | 8 (21.05) | 29.6817 |
| 2010's | 7 (18.42) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Litzow, MR | 1 |
| Wang, XV | 1 |
| Carroll, MP | 1 |
| Karp, JE | 1 |
| Ketterling, RP | 1 |
| Zhang, Y | 2 |
| Kaufmann, SH | 1 |
| Lazarus, HM | 1 |
| Luger, SM | 1 |
| Paietta, EM | 1 |
| Pratz, KW | 1 |
| Tun, HW | 1 |
| Altman, JK | 1 |
| Broun, ER | 1 |
| Rybka, WB | 1 |
| Rowe, JM | 1 |
| Tallman, MS | 1 |
| Rossato, LG | 1 |
| Costa, VM | 1 |
| Dallegrave, E | 1 |
| Arbo, M | 1 |
| Dinis-Oliveira, RJ | 1 |
| Santos-Silva, A | 1 |
| Duarte, JA | 1 |
| de Lourdes Bastos, M | 1 |
| Palmeira, C | 1 |
| Remião, F | 1 |
| Li, Y | 2 |
| Deng, Z | 1 |
| Zho, J | 1 |
| Ding, B | 1 |
| Shi, Y | 1 |
| Cheah, CY | 1 |
| Nastoupil, LJ | 1 |
| McLaughlin, P | 3 |
| Fanale, MA | 1 |
| Neelapu, SS | 1 |
| Fayad, LE | 1 |
| Hagemeister, FB | 3 |
| Fowler, NH | 1 |
| Larson, SM | 1 |
| Campbell, NP | 1 |
| Huo, D | 1 |
| Artz, A | 1 |
| Gajria, D | 1 |
| Green, M | 1 |
| Weiner, H | 1 |
| Daugherty, C | 1 |
| Odenike, O | 1 |
| Godley, LA | 1 |
| Hyjek, E | 1 |
| Gurbuxani, S | 1 |
| Thirman, M | 1 |
| Sipkins, D | 1 |
| Van Besien, K | 1 |
| Larson, RA | 1 |
| Stock, W | 1 |
| McLaughlin, B | 1 |
| Im, A | 1 |
| Raptis, A | 1 |
| Agha, M | 1 |
| Hou, JZ | 1 |
| Redner, R | 1 |
| Duggal, S | 1 |
| Lin, Y | 1 |
| Smith, C | 1 |
| Boyiadzis, M | 1 |
| Zinzani, PL | 1 |
| Pellegrini, C | 1 |
| Gandolfi, L | 1 |
| Casadei, B | 1 |
| Derenzini, E | 1 |
| Broccoli, A | 1 |
| Quirini, F | 1 |
| Argnani, L | 1 |
| Pileri, S | 1 |
| Celli, M | 1 |
| Fanti, S | 1 |
| Poletti, V | 1 |
| Stefoni, V | 1 |
| Baccarani, M | 1 |
| Tsimberidou, AM | 1 |
| Younes, A | 1 |
| Rodriguez, MA | 2 |
| Sarris, A | 1 |
| Romaguera, J | 1 |
| Hess, M | 1 |
| Smith, TL | 1 |
| Yang, Y | 1 |
| Ayala, A | 1 |
| Preti, A | 1 |
| Lee, MS | 1 |
| Cabanillas, F | 2 |
| Hainsworth, JD | 1 |
| Calvert, S | 1 |
| Greco, FA | 1 |
| Rigacci, L | 2 |
| Carpaneto, A | 1 |
| Alterini, R | 2 |
| Carrai, V | 1 |
| Bernardi, F | 2 |
| Bellesi, G | 2 |
| Longo, G | 2 |
| Bosi, A | 1 |
| Rossi Ferrini, P | 1 |
| Köppler, H | 1 |
| Heymanns, J | 1 |
| Pandorf, A | 1 |
| Weide, R | 1 |
| Di Costanzo, F | 1 |
| Manzione, L | 1 |
| Gasperoni, S | 1 |
| Bilancia, D | 1 |
| Acito, L | 1 |
| Angiona, S | 1 |
| Mazzoni, F | 1 |
| Giustini, L | 1 |
| Thomas, X | 1 |
| Elhamri, M | 1 |
| Chelghoum, Y | 1 |
| Reman, O | 1 |
| Arnaud, P | 1 |
| Raffoux, E | 1 |
| Le, QH | 1 |
| Tavernier, E | 1 |
| Dombret, H | 1 |
| Michallet, M | 1 |
| Wrzesień-Kuś, A | 1 |
| Robak, T | 1 |
| Wierzbowska, A | 1 |
| Lech-Marańda, E | 1 |
| Pluta, A | 1 |
| Wawrzyniak, E | 1 |
| Krawczyńska, A | 1 |
| Kuliczkowski, K | 1 |
| Mazur, G | 1 |
| Kiebiński, M | 1 |
| Dmoszyńska, A | 1 |
| Wach, M | 1 |
| Hellmann, A | 1 |
| Baran, W | 1 |
| Hołowiecki, J | 1 |
| Kyrcz-Krzemień, S | 1 |
| Grosicki, S | 1 |
| Tan, RM | 1 |
| Quah, TC | 1 |
| Aung, L | 1 |
| Liang, S | 1 |
| Kirk, RC | 1 |
| Yeoh, AE | 1 |
| Bezwoda, WR | 2 |
| Seymour, L | 2 |
| Dansey, RD | 1 |
| Sonneveld, P | 1 |
| de Ridder, M | 1 |
| van der Lelie, H | 1 |
| Nieuwenhuis, K | 1 |
| Schouten, H | 1 |
| Mulder, A | 1 |
| van Reijswoud, I | 1 |
| Hop, W | 1 |
| Lowenberg, B | 1 |
| Oza, AM | 1 |
| ten Bokkel Huinink, W | 1 |
| Dubbelman, R | 1 |
| Soepenberg, O | 1 |
| Mandjes, I | 1 |
| Aartsen, E | 1 |
| McVie, JG | 1 |
| Dugan, M | 1 |
| Choy, D | 1 |
| Ngai, A | 1 |
| Sham, J | 1 |
| Choi, P | 1 |
| Shiu, W | 1 |
| Leung, T | 1 |
| Teo, P | 1 |
| Prasad, U | 1 |
| Lee, S | 1 |
| Sanchiz, F | 1 |
| Milla, A | 1 |
| Stefanacci, S | 1 |
| Innocenti, F | 1 |
| Fusco, II | 1 |
| Di Lollo, S | 1 |
| Ferrini, PR | 1 |
| Okada, Y | 1 |
| Horikawa, K | 1 |
| Sano, M | 1 |
| Gregory, RK | 1 |
| Powles, TJ | 1 |
| Chang, JC | 1 |
| Ashley, S | 1 |
| de Forni, M | 1 |
| Lachau, S | 1 |
| Huguet, F | 1 |
| Canal, P | 1 |
| Laurent, G | 1 |
| Chevreau, C | 1 |
| Roche, H | 1 |
| Bugat, R | 1 |
| Ransom, DT | 1 |
| Neuberg, D | 1 |
| Loprinzi, CL | 1 |
| Tormey, DC | 1 |
| Blum, RH | 1 |
| Harris, JE | 1 |
| Asbury, RF | 1 |
| Falkson, G | 1 |
| Bhardwaj, S | 1 |
| Holland, JF | 1 |
| Velásquez, WS | 1 |
| Meistrich, ML | 1 |
| Liang, JC | 1 |
| Redman, JR | 1 |
| Romaguera, JE | 1 |
| Swan, F | 1 |
| Bishop, JF | 1 |
| Raghavan, D | 1 |
| Woods, R | 1 |
| Coates, A | 1 |
| Burns, I | 1 |
| Jeal, PN | 1 |
| Hillcoat, BL | 1 |
| Tattersall, MN | 1 |
| Henderson, IC | 1 |
| Allegra, JC | 1 |
| Woodcock, T | 1 |
| Wolff, S | 1 |
| Bryan, S | 1 |
| Cartwright, K | 1 |
| Dukart, G | 1 |
| Henry, D | 1 |
| Dansey, R | 1 |
| Ford, JM | 1 |
| Panasci, L | 1 |
| Leclerc, Y | 1 |
| Margolese, R | 1 |
| Vredenburgh, JJ | 1 |
| McIntyre, OR | 1 |
| Cornwell, GG | 1 |
| Ball, ED | 1 |
| Cornell, CJ | 1 |
| Mills, LE | 1 |
| O'Donnell, JF | 1 |
| Shenkenberg, TD | 1 |
| Von Hoff, DD | 1 |
| Pratt, CB | 1 |
| Vietti, TJ | 1 |
| Etcubanas, E | 1 |
| Sexauer, C | 1 |
| Krance, RA | 1 |
| Mahoney, DH | 1 |
| Patterson, RB | 1 |
| Esseesse, I | 1 |
| Bartolucci, AA | 1 |
| Gams, RA | 1 |
| Silberman, H | 1 |
| Velez-Garcia, E | 1 |
| Cohen, HJ | 1 |
| Omura, GA | 1 |
| Leiby, JM | 1 |
| Unverfurth, DV | 1 |
| Neidhart, JA | 1 |
| Hørding, U | 1 |
| Rose, C | 1 |
| Jakobsen, K | 1 |
| Dirksen, H | 1 |
| Ettinger, DS | 1 |
| Finkelstein, DM | 1 |
| Harper, GR | 1 |
| Ruckdeschel, JC | 1 |
| Chang, AY | 1 |
| Camacho, FJ | 1 |
| Marsh, JC | 1 |
| Silber, R | 1 |
| Wolter, JM | 1 |
2 reviews available for mitoxantrone and Hematologic Diseases
| Article | Year |
|---|---|
Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen: long-term follow-up results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etopo | 2003 |
Mitoxantrone: a new anticancer drug with significant clinical activity.
Topics: Adult; Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Child; Clinical Trials as T | 1986 |
22 trials available for mitoxantrone and Hematologic Diseases
| Article | Year |
|---|---|
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival | 2019 |
Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells.
Topics: Adolescent; Adult; Antigens, CD34; Antigens, CD7; Antineoplastic Combined Chemotherapy Protocols; Bl | 2014 |
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Communicabl | 2016 |
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2012 |
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Cispla | 2002 |
Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gastrointesti | 2002 |
Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; | 2004 |
Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Che | 2004 |
Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 2005 |
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Po
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; | 2005 |
High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1995 |
Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer.
Topics: Abdominal Pain; Female; Hematologic Diseases; Humans; Injections, Intraperitoneal; Middle Aged; Mito | 1994 |
Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanian Clinical Oncology Association Group study.
Topics: Adult; Aged; Carcinoma; Female; Hematologic Diseases; Humans; Male; Middle Aged; Mitoxantrone; Nasop | 1993 |
A randomised study comparing granulocyte-colony stimulating factor (G-CSF) with G-CSF plus thymostimulin in the treatment of haematological toxicity in patients with advanced breast cancer after high dose mitoxantrone therapy.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Female; Granulocyte Colon | 1996 |
A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etopo | 1996 |
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 1997 |
A pilot trial of TMM (thiotepa, mitoxantrone and methotrexate) chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hematologic D | 1990 |
Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.
Topics: Adenocarcinoma; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Female; He | 1989 |
Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1987 |
Mitoxantrone: a new anticancer drug with significant clinical activity.
Topics: Adult; Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Child; Clinical Trials as T | 1986 |
Phase II study of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study.
Topics: Aclarubicin; Aged; Anaphylaxis; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Azir | 1985 |
15 other studies available for mitoxantrone and Hematologic Diseases
| Article | Year |
|---|---|
Cumulative mitoxantrone-induced haematological and hepatic adverse effects in a subchronic in vivo study.
Topics: Animals; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Hematologic Diseases; Leukoc | 2014 |
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chrom | 2012 |
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Disease-Free S | 2013 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and | 2007 |
[Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy].
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Breast Neoplasms; Daunorub | 1997 |
Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases.
Topics: Adolescent; Adult; Aged; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Intraveno | 1991 |
A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1991 |
NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Follow-Up Studies; | 1990 |
Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Heart Diseases; Hematologic Diseas | 1987 |
First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fem | 1989 |
Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia.
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Drug Evaluation; Drug Resistance; Hema | 1988 |
Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study.
Topics: Adolescent; Adult; Anthraquinones; Antineoplastic Agents; Cardiomyopathies; Child; Child, Preschool; | 1986 |
Weekly mitoxantrone therapy for refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
Topics: Adult; Aged; Anthraquinones; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Lym | 1986 |
High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Dr | 1986 |
Mitoxantrone in advanced cervical carcinoma: a phase II study in patients not previously treated with chemotherapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Hematologic Diseases; Humans; Middle | 1986 |